PL2361936T3 - Cząsteczka wiążąca antygen i jej zastosowania - Google Patents

Cząsteczka wiążąca antygen i jej zastosowania

Info

Publication number: PL2361936T3
Authority: PL; Poland
Prior art keywords: antigen; binding molecule; molecule; binding
Prior art date: 2010-02-25

Application number

PL10154751.1T

Other languages

English (en)

Inventor

Melvyn Little

Gall Fabrice Le

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-02-25

Filing date

2010-02-25

Publication date

2016-10-31

2010-02-25 Application filed filed Critical

2016-10-31 Publication of PL2361936T3 publication Critical patent/PL2361936T3/pl

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Biophysics (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Life Sciences & Earth Sciences (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

PL10154751.1T 2010-02-25 2010-02-25 Cząsteczka wiążąca antygen i jej zastosowania PL2361936T3 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP10154751.1A EP2361936B1 (en)	2010-02-25	2010-02-25	Antigen-binding molecule and uses thereof

Publications (1)

Publication Number	Publication Date
PL2361936T3 true PL2361936T3 (pl)	2016-10-31

Family

ID=42232726

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL10154751.1T PL2361936T3 (pl)	2010-02-25	2010-02-25	Cząsteczka wiążąca antygen i jej zastosowania
PL11156113T PL2371866T3 (pl)	2010-02-25	2011-02-25	Wielowartościowa cząsteczka Fv wiążąca antygen

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL11156113T PL2371866T3 (pl)	2010-02-25	2011-02-25	Wielowartościowa cząsteczka Fv wiążąca antygen

Country Status (12)

Country	Link
EP (2)	EP2361936B1 (pl)
DK (1)	DK2371866T3 (pl)
ES (2)	ES2582001T3 (pl)
HR (1)	HRP20190288T1 (pl)
HU (1)	HUE041615T2 (pl)
LT (2)	LT2361936T (pl)
PL (2)	PL2361936T3 (pl)
PT (2)	PT2361936T (pl)
RS (1)	RS58352B1 (pl)
SI (1)	SI2371866T1 (pl)
SM (1)	SMT201900115T1 (pl)
TR (1)	TR201902400T4 (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2011373925B2 (en) *	2011-07-22	2016-04-28	Affimed Therapeutics Ag	Multivalent antigen-binding Fv molecule
UY35484A (es) *	2013-03-15	2014-10-31	Amgen Res Munich Gmbh	Molécula de unión de cadena simple que comprenden ABP de extremo N
US10647768B2 (en)	2014-05-29	2020-05-12	Macrogenics, Inc.	Multi-chain polypeptide-containing tri-specific binding molecules
MX2016017393A (es)	2014-07-01	2017-09-05	Pfizer	Diacuerpos heterodimericos biespecificos y sus usos.
US20170335009A1 (en) *	2014-10-31	2017-11-23	H. Lee Moffitt Cancer Center And Research Institute, Inc.	Tetravalent tlr9 bispecific antibody
CN107250161A (zh)	2015-01-26	2017-10-13	宏观基因有限公司	包含dr5‑结合结构域的多价分子
EP3770168A1 (en)	2015-05-18	2021-01-27	TCR2 Therapeutics Inc.	Compositions and methods for tcr reprogramming using fusion proteins
TWI773646B (zh)	2015-06-08	2022-08-11	美商宏觀基因股份有限公司	結合lag-3的分子和其使用方法
PE20231958A1 (es)	2015-07-30	2023-12-06	Macrogenics Inc	Moleculas de union a pd-1 y metodos de uso de las mismas
CN108367069B (zh)	2015-12-14	2022-08-23	宏观基因有限公司	对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法
AR108034A1 (es)	2016-02-17	2018-07-11	Macrogenics Inc	Moléculas de unión a ror1, y métodos de uso de las mismas
CN109069633A (zh)	2016-04-15	2018-12-21	宏观基因有限公司	新颖的b7-h3-结合分子、其抗体药物缀合物及其使用方法
WO2018026953A1 (en)	2016-08-02	2018-02-08	TCR2 Therapeutics Inc.	Compositions and methods for tcr reprogramming using fusion proteins
BR112019007100A2 (pt)	2016-10-07	2019-06-25	Tcr2 Therapeutics Inc	composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão
CN110177803A (zh)	2016-11-22	2019-08-27	T细胞受体治疗公司	用于使用融合蛋白进行tcr重新编程的组合物和方法
BR112019012950A2 (pt)	2016-12-23	2019-11-26	Macrogenics, Inc.	molécula de ligação a adam9, composição farmacêutica, uso da molécula de ligação a adam9 e método para tratar uma doença ou condição associada ou caracterizada pela expressão de adam9 em um indivíduo
AU2018226526B2 (en) *	2017-02-28	2025-03-13	Affimed Gmbh	Combination of an anti-CD16A antibody with a cytokine
WO2018158349A1 (en) *	2017-02-28	2018-09-07	Affimed Gmbh	Tandem diabody for cd16a-directed nk-cell engagement
US11795226B2 (en)	2017-12-12	2023-10-24	Macrogenics, Inc.	Bispecific CD16-binding molecules and their use in the treatment of disease
CN111787949A (zh)	2018-02-15	2020-10-16	宏观基因有限公司	变体cd3-结合结构域及其在用于治疗疾病的组合疗法中的用途
EP3774914A2 (en)	2018-04-13	2021-02-17	Affimed GmbH	Nk cell engaging antibody fusion constructs
AU2020279224B2 (en)	2019-05-21	2024-12-05	Novartis Ag	Trispecific binding molecules against BCMA and uses thereof
UY38701A (es)	2019-05-21	2020-12-31	Novartis Ag	Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE199392T1 (de)	1992-12-04	2001-03-15	Medical Res Council	Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
DE19819846B4 (de)	1998-05-05	2016-11-24	Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts	Multivalente Antikörper-Konstrukte
DE10060140A1 (de) *	2000-12-04	2002-06-06	Vectron Therapeutics Ag Imt	Multimerer mehrfach-antigenbindender einzelkettiger Antikörper
EP1500665B1 (en) *	2002-04-15	2011-06-15	Chugai Seiyaku Kabushiki Kaisha	METHODS FOR CONSTRUCTING scDb LIBRARIES
ES2559763T3 (es)	2002-09-10	2016-02-15	Affimed Gmbh	Anticuerpo humano específico de CD3 con propiedades inmunosupresoras
GB0510790D0 (en)	2005-05-26	2005-06-29	Syngenta Crop Protection Ag	Anti-CD16 binding molecules

2010
- 2010-02-25 LT LTEP10154751.1T patent/LT2361936T/lt unknown
- 2010-02-25 PL PL10154751.1T patent/PL2361936T3/pl unknown
- 2010-02-25 EP EP10154751.1A patent/EP2361936B1/en active Active
- 2010-02-25 PT PT101547511T patent/PT2361936T/pt unknown
- 2010-02-25 ES ES10154751.1T patent/ES2582001T3/es active Active
2011
- 2011-02-25 EP EP11156113.0A patent/EP2371866B1/en active Active
- 2011-02-25 RS RS20190201A patent/RS58352B1/sr unknown
- 2011-02-25 DK DK11156113.0T patent/DK2371866T3/en active
- 2011-02-25 ES ES11156113T patent/ES2711377T3/es active Active
- 2011-02-25 HU HUE11156113A patent/HUE041615T2/hu unknown
- 2011-02-25 SM SM20190115T patent/SMT201900115T1/it unknown
- 2011-02-25 LT LTEP11156113.0T patent/LT2371866T/lt unknown
- 2011-02-25 PL PL11156113T patent/PL2371866T3/pl unknown
- 2011-02-25 PT PT11156113T patent/PT2371866T/pt unknown
- 2011-02-25 TR TR2019/02400T patent/TR201902400T4/tr unknown
- 2011-02-25 SI SI201131675T patent/SI2371866T1/sl unknown
2019
- 2019-02-13 HR HRP20190288TT patent/HRP20190288T1/hr unknown

Also Published As

Publication number	Publication date
EP2361936B1 (en)	2016-04-20
LT2361936T (lt)	2016-09-12
HUE041615T2 (hu)	2019-05-28
DK2371866T3 (en)	2019-03-18
PT2361936T (pt)	2016-07-15
EP2361936A1 (en)	2011-08-31
ES2711377T3 (es)	2019-05-03
LT2371866T (lt)	2019-03-12
PL2371866T3 (pl)	2019-05-31
EP2371866B1 (en)	2018-11-21
SMT201900115T1 (it)	2019-02-28
SI2371866T1 (sl)	2019-04-30
HRP20190288T1 (hr)	2019-04-05
EP2371866A2 (en)	2011-10-05
TR201902400T4 (tr)	2019-03-21
PT2371866T (pt)	2019-02-27
EP2371866A3 (en)	2013-06-26
RS58352B1 (sr)	2019-03-29
ES2582001T3 (es)	2016-09-08

Publication	Publication Date	Title
LT2361936T (lt)	2016-09-12	Antigeną rišanti molekulė ir jos panaudojimas
DK2729170T3 (en)	2022-03-21	Antibody variants and uses thereof
IL232399A0 (en)	2014-06-30	Anti-2fgfr antibodies and their use
ZA201308879B (en)	2014-07-30	Anti-angptl3 antibodies and uses thereof
PT2581113T (pt)	2018-07-04	Anticorpo anti-tim-3
PL2530091T3 (pl)	2018-08-31	Przeciwciało przeciwko dll3
SI2946791T1 (sl)	2022-02-28	Protitelesa proti CD277 in uporabe le-teh
PL2616489T3 (pl)	2017-07-31	Przeciwciało anty-huTNFR1
SG11201401411TA (en)	2014-08-28	Meditopes and meditope-binding antibodies and uses thereof
EP2569012A4 (en)	2013-10-30	ANTI-FGFR2 ANTIBODY
IL229844B (en)	2022-02-01	Anti-psgl-1 antibodies and their use
PT2531518T (pt)	2016-08-12	Compostos oligopeptídicos e suas utilizações
GB201106357D0 (en)	2011-06-01	Composition and uses thereof
EP2716359A4 (en)	2014-04-23	COMPLEX AND USES THEREOF
GB201111775D0 (en)	2011-08-24	Compounds and uses thereof
GB201007957D0 (en)	2010-06-30	Antibody
AU4935P (en)	2014-10-21	FerrupenGL Pimelea ferruginea
GB201014319D0 (en)	2010-10-13	Compounds and uses thereof
GB201115285D0 (en)	2011-10-19	Biosensor and uses thereof
GB201017780D0 (en)	2010-12-01	Antibody
GB201013665D0 (en)	2010-09-29	Molecules
GB201121551D0 (en)	2012-01-25	Compounds and uses thereof
GB201121726D0 (en)	2012-02-01	Compounds and uses thereof
GB201019361D0 (en)	2010-12-29	Biosensor and uses thereof
GB201002019D0 (en)	2010-03-24	Powershot